PE20160899A1 - Derivados de acido heteroaril butanoico como inhibidores de lta4h - Google Patents

Derivados de acido heteroaril butanoico como inhibidores de lta4h

Info

Publication number
PE20160899A1
PE20160899A1 PE2016000846A PE2016000846A PE20160899A1 PE 20160899 A1 PE20160899 A1 PE 20160899A1 PE 2016000846 A PE2016000846 A PE 2016000846A PE 2016000846 A PE2016000846 A PE 2016000846A PE 20160899 A1 PE20160899 A1 PE 20160899A1
Authority
PE
Peru
Prior art keywords
butanoic acid
derivatives
heteroaryl
lta4h
inhibitors
Prior art date
Application number
PE2016000846A
Other languages
English (en)
Spanish (es)
Inventor
Birgit Bollbuck
Till Roehn
Wofgang Miltz
Christian Markert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20160899A1 publication Critical patent/PE20160899A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2016000846A 2013-12-20 2014-12-18 Derivados de acido heteroaril butanoico como inhibidores de lta4h PE20160899A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13199138 2013-12-20
EP14181155 2014-08-15

Publications (1)

Publication Number Publication Date
PE20160899A1 true PE20160899A1 (es) 2016-09-03

Family

ID=52434892

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000846A PE20160899A1 (es) 2013-12-20 2014-12-18 Derivados de acido heteroaril butanoico como inhibidores de lta4h

Country Status (38)

Country Link
US (4) US9981926B2 (cg-RX-API-DMAC7.html)
EP (1) EP3083564B1 (cg-RX-API-DMAC7.html)
JP (1) JP6500024B2 (cg-RX-API-DMAC7.html)
KR (2) KR102368958B1 (cg-RX-API-DMAC7.html)
CN (1) CN105829286B (cg-RX-API-DMAC7.html)
AP (1) AP2016009301A0 (cg-RX-API-DMAC7.html)
AU (1) AU2014369180B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016011170B1 (cg-RX-API-DMAC7.html)
CA (1) CA2927564C (cg-RX-API-DMAC7.html)
CL (1) CL2016001255A1 (cg-RX-API-DMAC7.html)
CR (1) CR20160279A (cg-RX-API-DMAC7.html)
CU (1) CU24360B1 (cg-RX-API-DMAC7.html)
CY (1) CY1120715T1 (cg-RX-API-DMAC7.html)
DK (1) DK3083564T3 (cg-RX-API-DMAC7.html)
EA (1) EA034436B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP16062173A (cg-RX-API-DMAC7.html)
ES (1) ES2690790T3 (cg-RX-API-DMAC7.html)
GT (1) GT201600132A (cg-RX-API-DMAC7.html)
HR (1) HRP20181506T1 (cg-RX-API-DMAC7.html)
HU (1) HUE039615T2 (cg-RX-API-DMAC7.html)
IL (1) IL245011B (cg-RX-API-DMAC7.html)
LT (1) LT3083564T (cg-RX-API-DMAC7.html)
MX (1) MX2016008247A (cg-RX-API-DMAC7.html)
MY (1) MY180165A (cg-RX-API-DMAC7.html)
NZ (1) NZ719169A (cg-RX-API-DMAC7.html)
PE (1) PE20160899A1 (cg-RX-API-DMAC7.html)
PH (1) PH12016500814B1 (cg-RX-API-DMAC7.html)
PL (1) PL3083564T3 (cg-RX-API-DMAC7.html)
PT (1) PT3083564T (cg-RX-API-DMAC7.html)
RS (1) RS57642B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201602787YA (cg-RX-API-DMAC7.html)
SI (1) SI3083564T1 (cg-RX-API-DMAC7.html)
SV (1) SV2016005230A (cg-RX-API-DMAC7.html)
TN (1) TN2016000127A1 (cg-RX-API-DMAC7.html)
UA (1) UA117498C2 (cg-RX-API-DMAC7.html)
UY (1) UY36178A (cg-RX-API-DMAC7.html)
WO (1) WO2015092740A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201602445B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102368958B1 (ko) 2013-12-20 2022-02-28 노파르티스 아게 Lta4h 억제제로서의 헤테로아릴 부탄산 유도체
WO2017175185A1 (en) 2016-04-08 2017-10-12 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
SG11202010115RA (en) 2018-05-15 2020-11-27 Alkahest Inc Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase
BR112021000964A2 (pt) 2018-07-25 2021-04-20 Novartis Ag inibidores do inflamassoma de nlrp3
AR115866A1 (es) 2018-07-31 2021-03-03 Novartis Ag Formas cristalinas de un inhibidor de lta4h
JP7279073B2 (ja) * 2018-11-07 2023-05-22 中外製薬株式会社 Ｏ－置換セリン誘導体の製造方法
EP4442315A3 (en) * 2019-01-11 2024-11-20 Novartis AG Lta4h inhibitor for the treatment or prevention of hidradenitis suppurativa
US10610280B1 (en) 2019-02-02 2020-04-07 Ayad K. M. Agha Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
WO2021044351A1 (en) 2019-09-06 2021-03-11 Novartis Ag Methods of treating liver disease using lta4h inhibitors
EP4196478A1 (en) 2020-08-14 2023-06-21 Novartis AG Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
US11932630B2 (en) * 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
JP2024542963A (ja) 2021-11-01 2024-11-19 アルカヘスト，インコーポレイテッド 加齢関連疾患の予防及び治療のためのロイコトリエンａ４加水分解酵素（ｌｔａ４ｈ）のベンゾジオキサン調節剤
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549831A1 (fr) 1983-07-27 1985-02-01 Rhone Poulenc Agrochimie Nouveaux derives d'acides aryloxybenzoiques, et leur utilisation comme herbicides
US4708965A (en) 1985-09-16 1987-11-24 Morgan Lee R Method of treating herpes virus infections with N,N'-diacetylcystine and derivatives
ES2031513T3 (es) 1986-08-21 1992-12-16 Pfizer Inc. Quinazolindionas y piridopirimidinadionas.
US5272167A (en) 1986-12-10 1993-12-21 Schering Corporation Pharmaceutically active compounds
US4851423A (en) 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
US5750532A (en) 1986-12-10 1998-05-12 Schering Corporation Pharmaceutically active compounds
CA1315279C (en) 1987-01-12 1993-03-30 Nancy Grace Bollinger Anti-inflammatory agents
US4820723A (en) * 1987-08-14 1989-04-11 Eli Lilly And Company Disubstituted tetrazole leukotriene antagonists and methods for their use thereas
US5055481A (en) 1989-03-24 1991-10-08 Wakamoto Pharmaceutical Co., Ltd. Tetrazole derivatives and aldose reductase inhibition therewith
AU6062590A (en) 1989-07-07 1991-02-06 Schering Corporation Pharmaceutically active compounds
WO1996036617A1 (en) 1995-05-19 1996-11-21 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
US6037345A (en) 1998-01-13 2000-03-14 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazolinedione and pyridopyrimidinedione derivatives
ES2251976T3 (es) 1999-02-11 2006-05-16 Emisphere Technologies, Inc. Compuestos y composiciones de oxadiazol para aportar agentes activos.
AU3468300A (en) 1999-02-26 2000-09-14 Jesper Z. Haeggstrom Drug design based on the structure of lta4 hydrolase
CN1353605A (zh) 1999-03-26 2002-06-12 欧洲凯尔特股份有限公司 芳基取代的吡唑、咪唑、噁唑、噻唑和吡咯及其应用
KR20030019372A (ko) 2000-05-09 2003-03-06 크레이톤 유니버시티 암세포의 증식 억제 및 세포사멸 유도 방법
US20020107244A1 (en) 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
US20020123490A1 (en) 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
US20020183306A1 (en) 2001-05-30 2002-12-05 Pfizer Inc. Combination treatment for sleep disorders including sleep apnea
AU2003247622A1 (en) * 2002-06-27 2004-01-19 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use
WO2004035741A2 (en) 2002-10-17 2004-04-29 Decode Genetics Ehf. Susceptibility gene for myocardial infarction; methods of treatment
GB0230025D0 (en) * 2002-12-23 2003-01-29 Pfizer Ltd Novel pharmaceuticals
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
EP1623231A2 (en) 2003-05-06 2006-02-08 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4)
US20050272051A1 (en) 2003-09-17 2005-12-08 Decode Genetics Ehf. Methods of preventing or treating recurrence of myocardial infarction
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
GB0410103D0 (en) 2004-05-06 2004-06-09 Biolipox Ab New method
WO2006008142A1 (en) 2004-07-20 2006-01-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and therapy of psoriasis vulgaris
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
GB0524786D0 (en) * 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
US7989480B2 (en) 2006-08-04 2011-08-02 Decode Genetics Ehf Aryl amino acid derivatives as inhibitors for treating inflammation
WO2008019284A1 (en) 2006-08-04 2008-02-14 Decode Genetics Ehf Phenoxymethylalkyne inhibitors of lta4h for treating inflammation
CA2672438A1 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
CL2008000468A1 (es) 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Uso de compuestos derivados de heterociclos, inhibidores de leucotrina a4 hidrolasa (lta4h), utiles para tratar o prevenir la dermatitis, acne, infarto al miocardio, dolor, picazon, gingivitis, cancer, artritis, entre otras.
EP1958631A1 (en) 2007-02-14 2008-08-20 AEterna Zentaris GmbH Novel triazole derivatives as ligands of G-protein coupled receptors
US8288357B2 (en) 2007-03-23 2012-10-16 Korea University Research & Business Foundation Use of inhibitors of leukotriene B4 receptor BLT2 for treating human cancers
JP2013532734A (ja) 2010-08-04 2013-08-19 ユニバーシティ オブ バージニア パテント ファウンデーション 炎症性疾患を治療するための組成物及び方法
EP2822548B1 (en) * 2012-02-08 2019-04-24 University of Virginia Patent Foundation Long chain base sphingosine kinase inhibitors
EP2827849A4 (en) 2012-03-23 2015-11-18 Univ Leland Stanford Junior TREATMENT OF PULMONARY HYPERTONIA WITH LEUKOTRIENHEMMERN
AR091786A1 (es) 2012-07-17 2015-02-25 Boehringer Ingelheim Int Inhibidores de la produccion de leucotrienos
WO2014165090A1 (en) 2013-03-13 2014-10-09 The Broad Institute, Inc. Compounds for the treatment of tuberculosis
US9303018B2 (en) 2013-07-15 2016-04-05 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
KR102368958B1 (ko) 2013-12-20 2022-02-28 노파르티스 아게 Lta4h 억제제로서의 헤테로아릴 부탄산 유도체

Also Published As

Publication number Publication date
IL245011B (en) 2019-07-31
GT201600132A (es) 2018-11-27
WO2015092740A1 (en) 2015-06-25
SV2016005230A (es) 2016-11-21
CA2927564C (en) 2022-09-20
BR112016011170A8 (pt) 2020-04-28
CA2927564A1 (en) 2015-06-25
KR102423640B1 (ko) 2022-07-22
DK3083564T3 (en) 2018-10-22
SG11201602787YA (en) 2016-07-28
HUE039615T2 (hu) 2019-01-28
MY180165A (en) 2020-11-24
US20180170887A1 (en) 2018-06-21
ZA201602445B (en) 2019-01-30
PH12016500814A1 (en) 2016-06-13
MX2016008247A (es) 2016-10-21
LT3083564T (lt) 2018-09-25
AU2014369180B2 (en) 2016-11-17
HRP20181506T1 (hr) 2018-11-02
EP3083564B1 (en) 2018-07-11
EA034436B1 (ru) 2020-02-07
TN2016000127A1 (en) 2017-10-06
PH12016500814B1 (en) 2019-05-08
US12378206B2 (en) 2025-08-05
US9981926B2 (en) 2018-05-29
ES2690790T3 (es) 2018-11-22
KR20160101065A (ko) 2016-08-24
KR102368958B1 (ko) 2022-02-28
PL3083564T3 (pl) 2018-12-31
NZ719169A (en) 2018-08-31
UY36178A (es) 2017-01-31
EA201691293A1 (ru) 2016-10-31
CU24360B1 (es) 2018-10-04
US20170015637A1 (en) 2017-01-19
RS57642B1 (sr) 2018-11-30
CY1120715T1 (el) 2019-12-11
CN105829286B (zh) 2019-05-31
ECSP16062173A (es) 2018-05-31
EP3083564A1 (en) 2016-10-26
CN105829286A (zh) 2016-08-03
IL245011A0 (en) 2016-05-31
SI3083564T1 (sl) 2018-10-30
CL2016001255A1 (es) 2016-11-18
CR20160279A (es) 2016-08-31
JP6500024B2 (ja) 2019-04-10
US20210340112A1 (en) 2021-11-04
KR20220028175A (ko) 2022-03-08
US20220411385A1 (en) 2022-12-29
US11453651B2 (en) 2022-09-27
AP2016009301A0 (en) 2016-06-30
UA117498C2 (uk) 2018-08-10
JP2017505293A (ja) 2017-02-16
PT3083564T (pt) 2018-11-07
BR112016011170B1 (pt) 2023-01-10

Similar Documents

Publication Publication Date Title
PE20160899A1 (es) Derivados de acido heteroaril butanoico como inhibidores de lta4h
GEP201706671B (en) Heterocyclyl compounds as mek inhibitors
BR112014030473A2 (pt) novo diazaespirocicloalcano e azaespirocicloalcano
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
CU24341B1 (es) Compuestos y composiciones orgánicas inhibidores del ácido graso sintetasa (fasn) útiles para el tratamiento del cáncer, infecciones virales, obesidad y diabetes
MY187479A (en) 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
PE20160654A1 (es) Compuestos de inhibidor de autotaxina
EA201500557A1 (ru) Антигельминтные соединения, композиции и способы их применения
UA108219C2 (uk) Протипаразитарні дигідроазолові сполуки та композиція, яка їх містить (варіанти)
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
BR112013002182A2 (pt) derivados de quinolina e inibidores de melk contendo os mesmos
BR112014004219A2 (pt) pirano[3,2-d][1,3]tiazol como inibidores de glicosidase
BR112013017635A2 (pt) inibidores de cyp11b, cyp17 e/ou cyp21
PH12015502192A1 (en) Novel compounds
CO6680645A2 (es) Inhibidores de oxadiazol de la producción de leucotrieno
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
EA201591122A1 (ru) Гетероциклическое соединение
CY1109766T1 (el) Παραγωγα αζαπεπτιδιου ως αναστολεις πρωτεασης hiv
PE20160523A1 (es) Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis
PE20150224A1 (es) Inhibidores del nampt
CR20130501A (es) Derivados novedosos de cefalosporinas y composiciones farmacéuticas de estos
PH12015500008A1 (en) Dimethyl-benzoic acid compounds
EA201690072A1 (ru) Состав, содержащий гиполипидемическое средство
BR112014004523A2 (pt) composto e composição aromatizante
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1